CompletedNot Applicable

Effectiveness of Low-intensity Laser on Pain in Patients With Supraspinatus Tendinopathy

Spain80 participantsStarted 2024-06-01

Plain-language summary

Tendinopathy is an inflammatory process that occurs in and around the tendon when both are affected by a certain injury. In the case of the supraspinatus muscle it is one of the most frequent causes of shoulder pain. To test the efficacy of laser treatment in reducing shoulder pain caused by supraspinatus muscle tendinopathy. A randomized controlled clinical trial was carried out in which a physiotherapy intervention was performed using therapeutic laser for four weeks, to observe the influence on the pain generated by supraspinatus muscle tendinopathy in the shoulder. A sample of 82 patients was recruited and randomly divided into two groups: experimental group and control group. Laser therapy was applied to the first group and to the second group it was applied as a placebo

Who can participate

Age range

30 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 30-65 years. * Present a 3 or higher on the visual analogue scale in the shoulder. * Adequate cognitive capacity for comprehension. * Tendinopathy of the rotator cuff confirmed by ultrasound at the study center, either by inflammation of the tendon, presence of hypoechoic zones, calcification, fibrillar disorganization and/or neovascularization in the supraspinatus muscle. * Pain in the proximal side of the arm that is aggravated by abduction. Exclusion Criteria: * Laser-specific contraindications (e.g., tumors, presence of pacemaker or defibrillator, pregnancy, etc.). * History of glenohumeral fracture and rheumatoid arthritis. * Rheumatic, neurological or structural polymyalgia affecting the joint. * Previous surgeries. * Pregnant or breastfeeding women. * Taking anticoagulants or antiaggregants. * Diabetes mellitus. * Cardiac dysfunctions. * Infiltrative and/or rehabilitative treatment in the two months prior to recruitment. * Pre-existing diseases associated with pain in the upper extremities. * Difficulties of follow-up. * Depression. * Treatment with another intervention, during the development of the study will not be able to perform.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Visual Analogue Scale

Timeframe: 12 weeks

Trial details

NCT IDNCT07013708

SponsorUniversidad Católica de Ávila

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-30

View on ClinicalTrials.gov More Tendinopathy trials